ERBB2 and breast carcinoma: Similar results were obtained when HER2+ SKBR3 breast cancer cells were treated with Herceptin to block HER2, and a reduction in LCN2 expression was observed, suggesting that LCN2 may be a downstream target of the HER2 pathway [79].